Compare Amgen, Inc. (AMGN) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Lumen Technologies Inc — how do they compare? Amgen, Inc. trades at $357.02 (market cap $196.12B), while Lumen Technologies Inc trades at $6.55 (market cap $6.93B). The key difference: Amgen, Inc. is far larger — about 28.3× Lumen Technologies Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | LUMN | |
|---|---|---|
Market Cap | $196.12B | $6.93B |
Sector | Health | Media |
52-Week High | $388.16 | $11.83 |
52-Week Low | $271.18 | $3.70 |
Enterprise Value | $241.41B | $18.56B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LUMN trades at $6.73, down 0.3% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$1.74B for 2025, though revenue remains substantial at $12.40B. Recent news highlights the acquisition of Alkira to bolster AI-era networking capabilities and cost-saving initiatives targeting $1B annually by 2027. Debt levels are high at $17.49B long-term, but leverage is trending downward.
The outlook is mixed: positive catalysts include strategic acquisitions and cost reductions, but persistent losses and high debt pose significant risks. Analyst consensus is cautious with a Hold rating predominating, though the $8.25 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
